Jasper Therapeutics Inc (JSPR)

Q: What's priced into Jasper Therapeutics Inc (JSPR) stock?

The evidence snapshot provides no valuation or market-expectations measures, so whether JSPR looks cheap or expensive versus peers cannot be assessed. The thesis therefore depends more on clinical and regulatory progress than on a documented expectations gap.

Q: What does the Jasper Therapeutics Inc (JSPR) outlook hinge on?

Over the multi-year view, the thesis hinges on KP-104 progress, advancement of briquilimab toward a potential BLA, and whether KP-701 reaches first-in-human studies after a planned Phase 1 filing. In the near term, weaker jobs data could weigh on healthcare names, while results and guidance from VRTX, REGN, and MRNA may signal whether the sector tailwind continues.

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$0.51+2.91%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Jasper Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.3
Annual ending 2026-12-31
Revenue	—	6M
EPS	—	-0.46
Annual ending 2027-12-31
Revenue	—	173,800
EPS	—	-0.517

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
reduce net loss to about -$1.17M by Q1 2026	Net loss dropped from $27M to $1M.	Improving	net loss stays above -$1.17M by 2026-Q1	Net income: $-2.76M FY2026-Q2; GAAP. Published target: net loss <= -$1.17M. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 14, 2026-2,760,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8dedad45-8ef4-4ca4-a67b-eb8c4ecae420. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
reduce operating loss to about -$11M by Q1 2026	Operating loss fell from $27M to $11M.	Intact	operating loss stays above -$11M by 2026-Q1	Operating income: $-9.207M FY2026-Q2; GAAP. Published target: operating loss <= -$11M. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 14, 2026-9,207,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8dedad45-8ef4-4ca4-a67b-eb8c4ecae420. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
maintain Nasdaq listing and avoid delisting notices	A primary condition in Jasper Therapeutics Inc's published investment case. The stated target is no delisting notice or transfer of listing.	Under Pressure	receipt of a delisting notice or failure to meet listing rules	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 4
2026-07-25	Unavailable	Unavailable	3 / 4
2026-07-26	Unavailable	Unavailable	3 / 4
2026-07-27	Unavailable	Unavailable	3 / 4
2026-07-28	Unavailable	Unavailable	3 / 4
2026-07-29	Unavailable	Unavailable	1 / 4
2026-07-30	Unavailable	Unavailable	1 / 4
2026-07-31	Unavailable	Unavailable	1 / 4
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	Unavailable	Unavailable	3 / 4
2026-08-03	Unavailable	Unavailable	1 / 4
2026-08-04	Unavailable	Unavailable	1 / 4
2026-08-05	Unavailable	Unavailable	1 / 4
2026-08-06	Unavailable	Unavailable	3 / 4
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	Unavailable	3 / 4
2026-08-09	Unavailable	Unavailable	1 / 4
2026-08-10	Unavailable	Unavailable	3 / 4
2026-08-12	Unavailable	Unavailable	3 / 4
2026-08-13	Unavailable	Unavailable	1 / 4
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 4
2026-08-16	Unavailable	Unavailable	3 / 4
2026-08-17	Unavailable	Unavailable	3 / 4
2026-08-18	Unavailable	Unavailable	3 / 4
2026-08-19	Unavailable	Unavailable	3 / 4
2026-08-20	Unavailable	$173,800	3 / 5
2026-08-21	Unavailable	$173,800	3 / 5
2026-08-22	Unavailable	$173,800	3 / 5
2026-08-23	Unavailable	$173,800	3 / 5
2026-08-24	Unavailable	$173,800	3 / 5
2026-08-25	Unavailable	$173,800	3 / 5
2026-08-26	Unavailable	$173,800	3 / 5
2026-08-27	Unavailable	$173,800	3 / 5
2026-08-28	Unavailable	$173,800	3 / 5
2026-08-29	Unavailable	$173,800	3 / 5
2026-08-30	Unavailable	$173,800	3 / 5
2026-08-31	Unavailable	$173,800	3 / 5
2026-09-01	Unavailable	$173,800	3 / 5
2026-09-02	Unavailable	$173,800	3 / 5
2026-09-03	Unavailable	$173,800	3 / 5
2026-09-04	Unavailable	$173,800	3 / 5
2026-09-05	Unavailable	$173,800	3 / 5
2026-09-06	Unavailable	$173,800	3 / 5
2026-09-07	Unavailable	$173,800	3 / 5
2026-09-08	Unavailable	$173,800	3 / 5
2026-09-09	Unavailable	$173,800	3 / 5
2026-09-10	Unavailable	$173,800	3 / 5
2026-09-11	Unavailable	$173,800	3 / 5
2026-09-12	Unavailable	$173,800	3 / 5
2026-09-13	Unavailable	$173,800	3 / 5
2026-09-14	Unavailable	$173,800	3 / 5
2026-09-15	Unavailable	$173,800	3 / 5
2026-09-16	Unavailable	$173,800	3 / 5
2026-09-17	Unavailable	$173,800	3 / 5
2026-09-18	Unavailable	$173,800	3 / 5
2026-09-19	Unavailable	$173,800	3 / 5
2026-09-20	Unavailable	$173,800	3 / 5
2026-09-21	Unavailable	$173,800	3 / 5
2026-09-22	Unavailable	$173,800	3 / 5
2026-09-23	Unavailable	$173,800	3 / 5
2026-09-24	Unavailable	$173,800	3 / 5
2026-09-25	Unavailable	$173,800	3 / 5
2026-09-26	Unavailable	$173,800	3 / 5
2026-09-27	Unavailable	$173,800	3 / 5
2026-09-28	Unavailable	$173,800	3 / 5
2026-09-29	Unavailable	$173,800	3 / 5
2026-09-30	Unavailable	Unavailable	3 / 1
2026-10-01	Unavailable	Unavailable	3 / 1
2026-10-02	Unavailable	Unavailable	3 / 1
2026-10-03	Unavailable	Unavailable	3 / 1
2026-10-04	Unavailable	Unavailable	3 / 1
2026-10-05	Unavailable	Unavailable	3 / 1
2026-10-06	Unavailable	Unavailable	3 / 1
2026-10-07	Unavailable	Unavailable	3 / 1
2026-10-08	Unavailable	Unavailable	3 / 1
2026-10-09	Unavailable	Unavailable	3 / 1
2026-10-10	Unavailable	Unavailable	3 / 1
2026-10-11	Unavailable	Unavailable	3 / 1
2026-10-12	Unavailable	Unavailable	3 / 1
2026-10-13	Unavailable	Unavailable	3 / 1
2026-10-14	Unavailable	Unavailable	3 / 1
2026-10-15	Unavailable	Unavailable	3 / 1
2026-10-16	Unavailable	Unavailable	3 / 1
2026-10-17	Unavailable	Unavailable	3 / 1
2026-10-18	Unavailable	Unavailable	2 / 2
2026-10-19	Unavailable	Unavailable	2 / 2
2026-10-20	Unavailable	Unavailable	2 / 2
2026-10-21	Unavailable	Unavailable	2 / 2
2026-10-22	Unavailable	Unavailable	2 / 2
2026-10-23	Unavailable	Unavailable	2 / 2
2026-10-24	Unavailable	Unavailable	2 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	4	4
2026-06-01	3	4
2026-07-01	3	3
2026-08-01	3	3
2026-09-01	3	3
2026-10-01	2	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

reduce net loss to about -$1.17M by Q1 2026Net income: $-2.76M
reduce operating loss to about -$11M by Q1 2026Operating income: $-9.207M
maintain Nasdaq listing and avoid delisting noticesPublished status: Under Pressure

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.8%Typical daily move · historical

Downside history

-85.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Jasper Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

JSPR is a speculative clinical-stage healthcare company, not a proven earnings compounder: it is loss-making and carries high risk. The thesis is intact, but confidence is low and management has been volatile, including a recent CEO transition.

What's priced into Jasper Therapeutics Inc

The evidence snapshot provides no valuation or market-expectations measures, so whether JSPR looks cheap or expensive versus peers cannot be assessed. The thesis therefore depends more on clinical and regulatory progress than on a documented expectations gap.

What the fundamentals likely do

Near term, JSPR remains loss-making, though its operating loss narrowed from $10.952 million in the first quarter of 2026 to $9.207 million in the second. The October update reported that 18 patients were enrolled in the KP-104 IgAN cohort and enrollment finished on schedule, but the company has not yet shown revenue-generating delivery; a next-quarter earnings miss risk is elevated.

What Jasper Therapeutics Inc hinges on